Powered by

-Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

May 15, 2020 - ENP Newswire
Financial Results

BASKING RIDGE - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ('Caladrius' or the 'Company'), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, along with researchers from Cedars-Sinai (Los Angeles), Mayo Clinic (Rochester, Minn.) and The Christ Hospital (Cincinnati), today presented full data results from the ESCaPE-CMD trial of Caladrius's autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular ...